Amphenol stock slips after Wall Street target hikes; earnings are the next test

Amphenol stock slips after Wall Street target hikes; earnings are the next test

New York, Jan 16, 2026, 14:09 ET — Regular session

Amphenol Corp (APH) shares dropped 1.1%, closing at $152.54 on Friday afternoon. The stock opened at $155 and moved within a range of $151.75 to $156.58, with roughly 5.4 million shares changing hands.

This shift is crucial since investors see Amphenol as a reliable source for data-center expansions, where high-speed connectors and cables are essential components. The key issue: will that demand stay strong this quarter, and can the newly acquired cable segment be smoothly integrated into the financials?

Amphenol on Thursday announced a mandatory “open offer” — a tender bid required under Indian takeover rules — to acquire up to 26% of ADC India Communications from public shareholders after gaining indirect control of the firm. The company set the offer price at 1,233.59 rupees per share (around $13.68), which could total about $16.4 million in cash if fully subscribed. The offer carries no minimum acceptance threshold. (Business Wire)

Goldman Sachs bumped up its price target on Amphenol to $183 from $165, maintaining a Buy rating. The upgrade is tied to what the firm calls “strong data center demand,” as noted in a research report shared by TheFly. (TipRanks)

BofA lifted its price target to $165 from $163 and kept a Buy rating, anticipating a quarterly beat alongside “conservative” guidance. The bank also bumped its fiscal 2026 revenue and EPS forecasts in the preview to $31.2 billion and $4.41, up from $30.0 billion and $4.21. (TipRanks)

UBS analyst Joseph Spak maintained a Buy rating and raised his price target to $174 from $152 in a note dated Jan. 14. (GuruFocus)

Earlier this month, the company wrapped up its acquisition of CommScope’s Connectivity and Cable Solutions business. CEO R. Adam Norwitt highlighted that the deal “adds significant fiber optic interconnect capabilities” for IT datacom and communications networks. Amphenol projects the unit will bring in around $4.1 billion in sales by 2026 and expects it to be roughly $0.15 accretive to earnings per share, excluding acquisition-related costs. (Amphenol Investors)

On Friday, TE Connectivity slipped 0.5%.

The SPDR S&P 500 ETF and Invesco QQQ ETF edged mostly flat, leaving the spotlight on individual company developments rather than broad market moves.

That said, the recent surge leaves the stock vulnerable if data-center orders slow or integration costs climb beyond what bulls anticipate. When expectations are razor-thin, even minor tweaks to guidance — management’s outlook — can weigh on the shares.

Amphenol’s scheduled fourth-quarter earnings call is set for Jan. 28 at 1:00 p.m. ET. Investors will be watching closely for any demand trends in IT and data communications, as well as initial insights into the cable unit’s performance. (Amphenol Investors)

Stock Market Today

  • National Bankshares lifts Cogeco Communications target to C$71; stock climbs
    January 16, 2026, 4:08 PM EST. Cogeco Communications (TSE:CCA) rose after National Bankshares raised its price target from C$66 to C$71, signaling a potential downside of 3.65% from the prior close. Other brokers offered mixed views: Scotiabank lifted its target to C$74.25 with a sector-perform rating; TD Securities increased to C$100 with a Buy; CIBC cut to C$68; Desjardins set C$71 with Hold; BMO Capital Markets trimmed to C$70. MarketBeat shows a Hold consensus and an average target around C$76.03. CCA traded up about C$2.83 to C$73.69 on volume of 194,603. Fundamentals: market cap about C$3.09B; P/E 10.08; debt-to-equity 159.35; beta 0.65. Analysts expect about C$8.49 in EPS for the year.
Spotify stock slips as $12.99 U.S. price hike lands; SPOT investors eye churn and Feb. 10 results
Previous Story

Spotify stock slips as $12.99 U.S. price hike lands; SPOT investors eye churn and Feb. 10 results

AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst
Next Story

AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

Go toTop